Why Patients Consider Switching Between These Treatments
Switching From Wegovy To Mounjaro: Stock Availability In The UK
The decision to switch from Wegovy to Mounjaro often stems from supply concerns, side effect profiles, or plateau effects in weight management. Unlike periods of shortage that affected both medications historically, EverydayMeds maintains consistent stock levels of both treatments through direct partnerships with Novo Nordisk and Eli Lilly. Our pharmacy (GPhC #9012878) processes orders within 24 hours, ensuring patients don't experience treatment gaps that could impact their weight management progress.
When switching from Wegovy to Mounjaro, timing is crucial as both are prescription-only medicines requiring careful transition protocols. Our clinical team coordinates switches to maintain therapeutic continuity, preventing the metabolic adjustments that can occur during treatment interruptions. This seamless availability distinguishes our service from providers who may experience stock fluctuations or extended lead times.
Pricing Comparison: Switching From Wegovy To Mounjaro Costs
Understanding the financial implications of switching from Wegovy to Mounjaro helps inform treatment decisions. Wegovy pricing starts at £79.99 for the 0.25mg starter dose, progressing to £209.99 for the 2.4mg maintenance dose, with new customers applying code FIRST40 and returning customers using DOSE25 at checkout. Our Intro Duo bundle (0.25mg & 0.5mg) costs £169.99, providing eight weeks of initial treatment. The Ultimate Stability Trio offers three months of maintenance 2.4mg doses for £649.99.
Mounjaro follows a different pricing structure reflecting its dual GIP/GLP-1 mechanism. When switching from Wegovy to Mounjaro, patients often find the dosing schedules differ, requiring recalculation of monthly treatment costs. Both treatments offer bundle options for convenience, reducing delivery frequency and ensuring continuous supply. Our transparent pricing eliminates hidden costs, with all fees disclosed upfront during the clinical assessment process.
Clinical Evidence: Why Patients Switch From Wegovy To Mounjaro
The STEP trial programme demonstrated Wegovy's efficacy, with STEP 1 showing approximately 15% average weight loss at 68 weeks versus 2.4% with placebo (Wilding et al., NEJM, 2021). However, individual responses vary significantly, leading some patients to consider alternatives. The SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events, extending Wegovy's clinical profile beyond weight management.
Mounjaro's SURMOUNT trials investigated tirzepatide's dual-action mechanism, combining GIP and GLP-1 receptor activation. Some patients switching from Wegovy to Mounjaro report different side effect profiles or renewed treatment response. Clinical assessment is essential when considering switches, as prescribers evaluate individual factors including treatment history, current health status, and weight management goals.
How Wegovy Works In Your Weight Management Journey
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics naturally occurring incretin hormones produced in your intestines. This medication works by binding to GLP-1 receptors in your brain's appetite control centres, reducing hunger signals and promoting feelings of fullness after smaller meals. The mechanism also slows gastric emptying, meaning food remains in your stomach longer, contributing to sustained satiety between meals. Clinical studies suggest Wegovy may help reduce food cravings, particularly for high-calorie, palatable foods that often undermine weight management efforts. These effects support patients in maintaining the reduced-calorie diet essential for successful weight management, whilst the weekly injection schedule promotes treatment adherence.
Seamless Ordering Process For Treatment Switching
Switching from Wegovy to Mounjaro through EverydayMeds begins with our comprehensive 3-minute online clinical assessment, capturing your treatment history, current health status, and reasons for considering the switch. Our qualified prescribers review each case within 3 working days (24 hours with express service), evaluating whether the proposed switch aligns with clinical guidelines and your individual circumstances. Upon approval, both treatments ship via next-day delivery using temperature-controlled cold-chain logistics, maintaining medication integrity from our pharmacy to your door. The process includes detailed administration guidance, dose escalation schedules, and ongoing clinical support throughout your treatment journey. Our GPhC-registered pharmacy (#9012878) ensures all regulatory requirements are met whilst minimising delays in treatment transitions.
Storage Considerations When Switching Between Treatments
Both Wegovy and Mounjaro require refrigerated storage at 2-8°C before first use, though their room temperature stability differs significantly. Wegovy pens can remain at room temperature below 30°C for up to 6 weeks once removed from refrigeration, whilst Mounjaro maintains stability for only 21 days at room temperature. This storage advantage makes Wegovy more suitable for travel or patients with inconsistent refrigerator access. The FlexTouch pen system used by Wegovy provides precise dose delivery through its established injection mechanism, whilst Mounjaro utilises Eli Lilly's KwikPen technology. Both treatments follow mandatory dose escalation protocols - patients cannot skip dose increases as this increases side effect risks and reduces treatment tolerability. Each pen contains four weekly doses, requiring monthly prescription renewals to maintain treatment continuity.
Supply Chain Reliability For Switching From Wegovy To Mounjaro In The UK
EverydayMeds has developed robust supply relationships with both Novo Nordisk and Eli Lilly, ensuring consistent availability when patients need to switch from Wegovy to Mounjaro. Our inventory management system tracks stock levels across all dose strengths, preventing the supply disruptions that previously affected patient care. We maintain strategic reserves of both medications, particularly the starter and maintenance doses most commonly prescribed during treatment switches.
This supply reliability eliminates the treatment gaps that can compromise weight management progress. When patients experience delays between stopping one medication and starting another, metabolic adjustments can reverse previous benefits. Our same-day prescription processing and assured next-day delivery ensure seamless transitions, supported by clinical monitoring to optimise switch timing and minimise potential side effects.
Complete Your Treatment Switch With Expert Support
Ready to explore switching from Wegovy to Mounjaro with Reliable UK stock availability? Our clinical team at EverydayMeds provides comprehensive switch management, ensuring therapeutic continuity whilst you transition between treatments. Apply discount code FIRST40 for new customers or DOSE25 for returning patients at checkout to access our competitive pricing structure. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment today, with express prescriber review available for urgent switches. Both Wegovy and Mounjaro remain in stock with immediate shipping available across the UK. Our expert pharmacists provide ongoing support throughout your treatment journey, ensuring optimal outcomes from your weight management programme.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
